Valeria Pecci, Fabiola Troisi, Aurora Aiello, Sara De Martino, Angela Carlino, Vincenzo Fiorentino, Cristian Ripoli, Dante Rotili, Francesco Pierconti, Maurizio Martini, Manuela Porru, Francesco Pinto, Antonello Mai, Pier Francesco Bassi, Claudio Grassi, Carlo Gaetano, Alfredo Pontecorvi, Lidia Strigari, Antonella Farsetti, Simona Nanni
BACKGROUND: About 30% of Prostate cancer (PCa) patients progress to metastatic PCa that remains largely incurable. This evidence underlines the need for the development of innovative therapies. In this direction, the potential research focus might be on long non-coding RNAs (lncRNAs) like H19, which serve critical biological functions and show significant dysregulation in cancer. Previously, we showed a transcriptional down-regulation of H19 under combined pro-tumoral estrogen and hypoxia treatment in PCa cells that, in turn, induced both E-cadherin and β4 integrin expression...
February 5, 2024: Cancer Cell International